Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ReViral","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"ReViral","sponsor":"CR-CP Life Science Fund","pharmaFlowCategory":"D","amount":"$44.0 million","upfrontCash":"Undisclosed","newsHeadline":"ReViral Raises $44 Million in Series C Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"ReViral","sponsor":"LianBio","pharmaFlowCategory":"D","amount":"$119.0 million","upfrontCash":"$14.0 million","newsHeadline":"ReViral and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Sisunatovir in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"ReViral","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReViral Announces Positive Recommendation by the Data Safety Monitoring Committee to Continue the Phase 2 Clinical Study of Sisunatovir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"ReViral","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$525.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"ReViral","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$525.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pfizer Completes Acquisition of ReViral","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by ReViral

    Menu

    ReViral

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ReViral

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Pfizer Completes Acquisition of ReViral

              Details:

              ReViral brings to Pfizer a portfolio of promising therapeutic candidates, including RV521 (sisunatovir), an orally administered inhibitor designed to block fusion of the RSV virus to the host cell.

              Lead Product(s): Sisunatovir

              Therapeutic Area: Infections and Infectious Diseases Product Name: RV521

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Pfizer Inc

              Deal Size: $525.0 million Upfront Cash: Undisclosed

              Deal Type: Acquisition June 09, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ReViral

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates

              Details:

              Proposed acquisition strengthens Pfizer’s capabilities in infectious disease research and development with a promising therapeutic candidates, including sisunatovir, an orally administered inhibitor designed to block fusion of the RSV virus to the host cell.

              Lead Product(s): Sisunatovir

              Therapeutic Area: Infections and Infectious Diseases Product Name: RV521

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Pfizer Inc

              Deal Size: $525.0 million Upfront Cash: Undisclosed

              Deal Type: Acquisition April 07, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ReViral

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ReViral Announces Positive Recommendation by the Data Safety Monitoring Committee to Continue the Phase 2 Clinical Study of Sisunatovir

              Details:

              REVIRAL1 study evaluate safety, tolerability, pharmacokinetic profile, antiviral effects, and clinical effect of single and multiple oral doses of sisunatovir in healthy infants between ages of 1 and 36 months hospitalized with RSV lower respiratory tract infections.

              Lead Product(s): Sisunatovir

              Therapeutic Area: Infections and Infectious Diseases Product Name: RV521

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 16, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ReViral

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ReViral and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Sisunatovir in China

              Details:

              Sisunatovir is ReViral’s lead small molecule for the treatment of RSV, currently in Phase 2 clinical studies in pediatric and adult immunocompromised patient populations.

              Lead Product(s): Sisunatovir

              Therapeutic Area: Infections and Infectious Diseases Product Name: RV521

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: LianBio

              Deal Size: $119.0 million Upfront Cash: $14.0 million

              Deal Type: Collaboration March 02, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ReViral

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ReViral Raises $44 Million in Series C Financing

              Details:

              The proceeds from the financing will be used to support Phase 2 clinical development for sisunatovir, ReViral's wholly-owned fusion protein inhibitor, and to progress our N-protein replication inhibitor program into Phase 1.

              Lead Product(s): Sisunatovir

              Therapeutic Area: Infections and Infectious Diseases Product Name: RV521

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: CR-CP Life Science Fund

              Deal Size: $44.0 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing August 25, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ReViral

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus Infection

              Details:

              Sisunatovir is the company’s most advanced product candidate, with two international multicentre Phase 2 clinical studies recently initiated in pediatric and high-risk adult patient populations.

              Lead Product(s): Sisunatovir

              Therapeutic Area: Infections and Infectious Diseases Product Name: RV521

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 04, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY